Our M&A lawyers are among the most experienced and effective in the world. We represent many of the world's largest publicly traded and privately held companies, as well as leading private equity firms on their most important mergers, acquisitions and takeover transactions.
Merck to Acquire Prometheus Biosciences in $10.8 Billion Deal
- Client News
- April 16, 2023
Paul, Weiss is representing Merck in its all-cash $10.8 billion acquisition of Prometheus Biosciences, Inc. Merck will acquire the company for $200 per share under the deal, and expected to close in the third quarter of 2023, pending regulatory approvals and other conditions.
Prometheus is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases.
The Paul, Weiss team is led by Laura Turano, Scott Barshay and Jennifer Wang, and includes corporate partner Christodoulos Kaoutzanis; intellectual property partner Jonathan Ashtor and counsel Bonnie Chen; executive compensation partner Jarrett Hoffman; real estate partner Peter Fisch; tax counsel Alyssa Wolpin; litigation counsel Steven Herzog; and environmental counsel William O’Brien.